LRA Congratulates Equillium on Positive Results of Study of Potential New Lupus Treatment
March 30, 2021 Equillium, Inc. announced positive topline data from the phase 1b EQUALISE study in patients with systemic lupus erythematosus (SLE). This study suggests that itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated among people with SLE. [Source: Equillium, Inc. Press Release 3.30.21] The EQUALISE study is evaluating […] Read More